Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011
Dispatch

Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland

Alain Kenfak-Foguena1, Franziska Schöni-Affolter1, Philippe Bürgisser, Andrea Witteck, Katharine E.A. Darling, Helen Kovari, Laurent Kaiser, John-Marc Evison, Luigia Elzi, Vanina Gurtner De La Fuente, Josef Jost, Darius Moradpour, Florence Abravanel, Jacques Izopet2, Matthias Cavassini2Comments to Author , and the Swiss HIV Cohort Study
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Vaudois and Lausanne University, Lausanne, Switzerland (A. Kenfak-Foguena, P. Bürgisser, K.E.A. Darling, D. Moradpour, M. Cavassini); Data Center of the Swiss HIV Cohort Study, Lausanne (F. Schöni-Affolter); Cantonal Hospital St. Gallen, St. Gallen, Switzerland (A. Witteck); University of Zurich, Zurich, Switzerland (H. Kovari); University Hospital Geneva, Geneva, Switzerland (L. Kaiser); Inselspital Klinik und Poliklinik für Infektiologie, Bern, Switzerland (J.-M. Evison); Universitätsspital Klinik für Infektiologie, Basel, Switzerland (L. Elzi); Ospedale Civico Servizio Malattie Infettive, Lugano, Switzerland (V. Gurtner-De La Fuente); Klinik Im Park, Zurich (J. Jost); Centre Hospitalier Universitaire de Toulouse, Toulouse, France (F. Abravanel, J. Izopet)

Main Article

Figure 1

Longitudinal description of blood hepatitis E virus (HEV) serology, HEV RNA, alanine aminotransferase (ALT) levels, HIV RNA, and CD4 count in patient with chronic HEV infection, positive results by real-time PCR for HEV RNA, and seroconversion to immunoglobulin (Ig) G. HAART, highly active antiretroviral therapy.

Figure 1. Longitudinal description of blood hepatitis E virus (HEV) serology, HEV RNA, alanine aminotransferase (ALT) levels, HIV RNA, and CD4 count in patient with chronic HEV infection, positive results by real-time PCR for HEV RNA, and seroconversion to immunoglobulin (Ig) G. HAART, highly active antiretroviral therapy.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external